Member Info for Spuddymadrid

Great results today from Poolbeg. Very well run company as the prudent cash management shows. The strategy is wuite clear. Firm up a partnership deal in the coming months for Polb-001 with an upfront cash payment and use the funds to aquire cash generating and near cash generating products such as tPTX. Very hsppy to have a good sized holding here

Hello Moniman. Hope you are well. Yes it will be interesting to see the results. Checked the Poolbeg website and for the first time I see there are no upcoming events scheduled. Normally they schedule webinars, pharma exhibitions et cetera et cetera. Hopefully this is a good sign and points to a deal being signde off as they seem to be focussing their efforts elsewhere at the moment. Regards

Hello there Moniman. Hope you are well. Agree with you on CF. He puts his money where his mouth is !!!. So the year end results are late this year. Wonder if they are trying to tie up a deal before releasing the results. Take care

Hello there Swizz. Thank you very much for your comments. You are a Gentleman. I think most on this site really appreciate the effort and time you took. Interesting times ahead. Fingers crossed. We might salvage something yet. Sad situation though that a bunch of zealots and career politicians have not take the best interest of the Country at heart and have destroyed the potential oil and gas industry in Ireland. Take care regards Spuddy

Hello there Adzy. Yes and with confirmation that two large Pharmas are interested in the phase 2 clinical trials and likely looking to take part the SP at anything above 9 pence is a steal !!!

Thanks Cash

Sounds about right. Complex enough I imagine to ensure all parties involved get a good deal. Hopefully we will see the SP start to rise. Perhaps we migh also hear some news regarding expansion of patent protection for POLB-001 in other indications. We should hear some news soon enough on the GLP trial. wonder what is happening with the Nasdaq listed company who are testing our oral delivery play. RSV AI side is quiet. Poolbeg was supposedly looking at existing drugs that had been sidelined for other indications that could potentially be repositioned for RSV. Would like to know what is happening here and what might be the interest. POLB-002 no word. And then of course there is the Influenza AI clinical vaidiation that is ongoing.

Hello there Swizz. Hope all well with you. Very happy to see that there is still some integrity around. The fact that existing shareholders will be protected according the CEO is testament to this. Sad that another Gentleman with the power to show some decency toward the long term shareholders of BOE behaved diffently. As they say ^ Much wants More ^. Anyway will hold and keep my fingers crossed. I hope that we get something back and I am sure that many small shareholders would like to thank the CEO for his integrity. GLA

Thanks very much Cash. Looking good. Just requires patience. Could not find the telegram chat group. But what you said sounds very promising. Polb-001 would be a nice fit for Pfizer and a biddiing war would be very much welcolmed. Wonder how such a deal might be structured, especially if there is more than one company interested. Would the interested parties bid for right purpose to conduct trials. JS mentioned one Pharma company looking to do trials by the year end and on the back of positive readouts progress to parthenrship. So trying to figure out whether any potential parties would be bidding against each other before or after trials. And if after how would that work if one of the interested parties had previously been involved in the trial.

Hello there Cash. How are things. Do you have the link to the telegram group by any chance

take care

Spuddy

Hello there Bazzman. How are things. Yes it is a tree shake but in the absence of any news in any direction this was always going to happen. We need to hear some concrete progress. It is obvious that day traders and MMs and shorters will take advantage whilst we hear nothing new. I believe we will but it is annoying to see the share price action and one needs alot of patience whilst invested here

Thanks for that confirmation Moniman. At least they have a target to reach that is easier without dillution

Should have said 17.945 pence and not 19.945 pence !!!

Hello there Moniman. Hope all well with you. Yes annoying to see SP drift lower but not surprising given the lack of concrete newsflow at present. I did not see mentioned anywhere in the EIP any expiry date. The one good point with the EIP is that there is a benefit to growing the share price rather than dilluting the share. Whilst I expect that we will see some dillution of our holdings at some stage I think we are now more likely to see the managment team focus on share price growth through parterning ahead of any equity based in -license or equiity based takeover. Also as these are share options in order for them to be worthwhile the share price would have to be considerably over 19.945 pence.

Thanks very much for that Cash. Much appreciated. Regards

Hello Cash

Hope you are well. Do you have a link to the mello youtube presentation ? take care

Get the impression that today`s RNS is directed toward any future possible merger or equity based in licensing partner. Imagine we were looking to inlicense or allot shares for a potential inlicensed ophan drug partner. It could be a message to say we expect Poolbeg to be quite a valuable company in the future and thus if you want in you will have to reduce your equity expectations in order to do a deal.

Morning Trout. Agree very hard to see how one of the major Pharmas will not want to get involved here and corner the market. Also think that David alluded to the fact that they might look for Orphan Status for Polb-001. That might speed things up and if granted could make Polb-001 a much higher value and nearer term value generating proposition !!!

Hello Swizz. How are you keeping ? Do you think we will hear some news soon. Very quiet at the moment. Nothing from Vevan either !!

Hello there Makeaboundle. Yes it requires a lot of patience waiting for something to happen here. There has to be an advantage to waiting for LG and Vevan. If not why not just advance the ECT case. One possibility is that LG and Vevan are in discussions with the DECC regarding their future plans. LG might be telling the DECC that unless the license is restored they will begin litigation in the courst to have it reinstated. LG and Vevan might also be examining whether they can go the ECT route now that Vevan is a Jersey based company. If Vevan have no legal right obviously then the next area to examine is whether Vevan can reverse into LOGP and put in an ECT claim for 100% of the damages. If in the end only LOGP can make a claim I see the Irish Government settling quickly so as to shut down the whole afffair and not get bad publicity. Perhaps LOGP and the Irish Government can agree to a decent but modest settlment. 50-75M for example. Anyway let us see what Swizz thinks. He has a better handle on all this !!!

Hello there Cash. Whilst this all sounds good I hope they do not do the same thing as they did in Amryt. I held for many years and originally the market cap was around 80-100 million. It was sold for circa 1.4bn. Looks great on paper. But if you dig deeper not so great. So share price was around 20-24 pence at launch. Then they did the reverse take over of algerion (1 for 6 dillution). Then the did the Nasdaq ADR 5 for 1 conversion. And then they merged with Chiasma with further dilution. I worked it out before and I made just 67% over the entire 6 years. So not the huge return that the market cap growth from 80m to 1.4bn would suggest. Also they gave themselves generous options at each stage of these consolidations and mergers. So original shareholders did not get a great deal. I want Poolbeg to first partner their existing POLB-001 so that we the existing shareholders who have taken the risk will be rewarded by the increase in market cap. Poolbeg does not urgently need cash so they should wait do a partnering deal and thereafter look at new products. I only see a benefit if any new in-licensing is on a royalty basis or for very small fee or a very small dilution.